Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 54.28

-0.5%

12:49 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Sam Citron who wrote (7467)	12/10/2002 3:38:16 PM
From: JFitnich	Read Replies (1) of 52153

I'll disagree with you there. Bureaucracies take awhile to turn the ship around. Thinking at the FDA does not change overnight. An example of this is the FDA meeting for Iressa (AZN) that took place a couple of months ago. Anyone who read through the minutes of the FDA meeting could tell that the drug had an impact on patients' lives. By reading through the minutes for the meeting, you can also get a read on what kind of info the FDA will be looking for in the future, not just from AZN, but from OSIP, ABGX, & IMCL, all companies with similiar drugs. If you happen to be an investor in any of these companies (I own ABGX) this information is excellent for determining what types of trials and what results the FDA is going to be looking for. I assure you, the "half-life" is longer than 5 minutes. JF

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next